• Explore /
  • Poster
  • / Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS).

Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS).

Abstract Poster

Authors

null

Andrew Eugene Hendifar

Sarcoma Oncology Center, Santa Monica, CA

Andrew Eugene Hendifar , Sant P. Chawla , Michael Gordon Leahy , Antoine Italiano , Shreyaskumar Patel , Armando Santoro , Arthur P. Staddon , Nicolas Penel , Sophie Piperno-Neumann , George D. Demetri , Larry Hayward , Jeff White , Launce G. Gouw , Bernardo De Miguel , Pilar Lardelli , Arturo Soto , Antonio Nieto , Jean-Yves Blay

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT00796120

Citation

J Clin Oncol 31, 2013 (suppl; abstr 10517)

DOI

10.1200/jco.2013.31.15_suppl.10517

Abstract #

10517

Poster Bd #

10

Abstract Disclosures

Similar Posters

First Author: Jean-Yves Blay

First Author: Erlinda Maria Gordon

First Author: Makoto Endo

First Author: Kathrin Heinrich